Clinical Trials Directory

Trials / Completed

CompletedNCT02077127

Monocyte Chemoattractant Protein-1 2518A/G Polymorphism

Association of Monocyte Chemoattractant Protein-1 (MCP-1)2518A/G Polymorphism With Proliferative Diabetic Retinopathy in Northern Chinese Type 2 Diabetes

Status
Completed
Phase
Study type
Observational
Enrollment
1,043 (actual)
Sponsor
Harbin Medical University · Academic / Other
Sex
All
Age
41 Years – 68 Years
Healthy volunteers
Not accepted

Summary

The pathogenesis of proliferative diabetic retinopathy (PDR) remains poorly understood. Recent studies have implicated that monocyte chemoattractant protein-1 (MCP-1) is associated with diabetic microvascular or macrovascular complications. However, the relationship between SNP polymorphism c.2518A/G in the MCP-1 gene with diabetic retinopathy remains controversial. In the present study, we evaluated the association of a single nucleotide polymorphism (SNP) in the MCP-1 gene with diabetic retinopathy (DR) and diabetic macular edema (DME) in Chinese population from Southern China with type 2 diabetes.

Detailed description

The association between polymorphism of MCP-1 c.2518A/G and DR had been reported in Japan and Korea, but their opinion were inconsistent. However there is no report in China so far. This study was designed to clarify the relationship of polymorphism of MCP-1 c.2518A/G with type 2 diabetes with or without DR. The relationship between MCP-1 c.2518A/G and different stage of DR has also been studied.This article proved that the MCP-1 c.2518G/G genotype is a susceptibility gene for DR in Chinese type 2 diabetic patients, especially the High-risk PDR. There is no association with DME and c.2518G/G.

Conditions

Timeline

Start date
2011-09-01
Primary completion
2013-02-01
Completion
2013-04-01
First posted
2014-03-04
Last updated
2014-03-05

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02077127. Inclusion in this directory is not an endorsement.